CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Metrics to compare | 5CV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship5CVPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −4.9x | −0.6x | |
PEG Ratio | −0.16 | −0.01 | 0.00 | |
Price/Book | 1.8x | 2.2x | 2.6x | |
Price / LTM Sales | 10.6x | 7.1x | 3.1x | |
Upside (Analyst Target) | - | 42.0% | 55.7% | |
Fair Value Upside | Unlock | 4.0% | 6.8% | Unlock |